Table 1.
Baseline information of SLE patients (n = 45)
| Baseline characteristics | ALL | stable | active | NP-SLE | P |
|---|---|---|---|---|---|
| n | 45 | 15 | 15 | 15 | |
| Age (years) | 36.53 ± 13.54 | 38.00 ± 13.46 | 32.53 ± 11.60 | 39.07 ± 15.30 | 0.375 |
| Female (n) | 39 | 13 | 13 | 13 | |
| Median SLEDAI (interquartile) | 12.0 (3.0, 17.0) | 2.0 (0,3.0) | 12.0 (10.0,20.0) | 15.0 (12.0,22.0) | < 0.001 |
| Laboratory tests | |||||
| Positive ANA (n) | 45 | 15 | 15 | 15 | – |
| Positive anti-dsDNA (n) | 28 | 8 | 9 | 11 | 0.516 |
| Hypocomplementaemia (n) | 24 | 6 | 7 | 10 | 0.315 |
| LDL-c (mmol/L) | 2.85 ± 1.48 | 2.32 ± 0.86 | 3.02 ± 2.21 | 2.73 ± 1.33 | 0.478 |
| HDL-c (mmol/L) | 1.12 ± 0.43 | 1.16 ± 0.39 | 1.37 ± 0.80 | 1.11 ± 0.43 | 0.416 |
| Triglycerides (mmol/L) | 1.93 ± 1.20 | 1.53 ± 0.81 | 2.62 ± 1.70 | 1.76 ± 1.09 | 0.056 |
| Apo-A1 (g/L) | 0.95 ± 0.31 | 1.04 ± 0.32 | 0.89 ± 0.27 | 0.98 ± 0.33 | 0.413 |
| Apo-B (g/L) | 0.88 ± 0.38 | 0.69 ± 0.24 | 0.98 ± 0.43 | 0.89 ± 0.35 | 0.078 |
|
SCr (μmol/L) (interquartile) |
59.0 (45.5104.5) | 52.0 (45.0,59.0) | 75.0 (50.0,153.0) | 47.0 (66.0,107.0) | 0.406 |
|
eGFR(ml/min∙1.73m2) (interquartile) |
62.0 (50.0,85.8) | 52.0 (45.0,58.0) | 76.0 (54.0,120.0) | 66.0 (58.3103.3) | 0.055 |
| 24-h urine protein (mg/L) (interquartile) | 294.0 (86.0,1219.0) | 170.0 (111.0,831.6) | 568.0 (61.0,2126.0) | 202.0 (471.0,5036.5) | 0.646 |
|
C3 (g/L) (interquartile) |
0.82 (0.59,1.03) | 0.98 (0.86,1.10) | 0.62 (0.46,9.00) | 0.80 (0.52,1.01) | 0.059 |
|
C4 (g/L) (interquartile) |
0.16 (0.08,0.24) | 0.19 (0.12,0.23) | 0.10 (0.04,0.43) | 0.15 (0.08,0.24) | 0.372 |
| Comorbidities | |||||
| Hypertension (n) | 15 | 3 | 7 | 5 | 0.301 |
| Diabetes mellitus (n) | 2 | 0 | 2 | 0 | 1.000 |
| Hyperlipidaemia (n) | 9 | 4 | 4 | 1 | 0.235 |
| PAH (n) | 8 | 2 | 3 | 3 | 0.854 |
| Current medications | |||||
| Prednisone (n) | 43 | 15 | 13 | 15 | 1.000 |
| Mycophenolate mofetil (n) | 15 | 4 | 7 | 4 | 0.407 |
| Cyclophosphamide (n) | 12 | 5 | 4 | 3 | 0.709 |
| Azathioprine (n) | 6 | 2 | 3 | 1 | 0.549 |
| Hydrochloroquine (n) | 44 | 15 | 14 | 15 | 1.000 |
| Cyclosporin/tacrolimus(n) | 8 | 3 | 4 | 1 | 0.307 |
| ACE inhibitors/ARB (n) | 28 | 8 | 10 | 10 | 0.685 |
Normally distributed measurement data were shown as ± s, and analyzed by the F-test. Otherwise, they were expressed as P50 (P25, P75), and compared by the Bonferroni correction. Enumeration data were shown as n (%), and analyzed through the Chi-square test
ANA, anti-nuclear antibody; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; Apo-A, apolipoprotein A; Apo-B, apolipoprotein B; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; PAH, pulmonary arterial hypertension; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker